Menlo Therapeutics Initiates Enrollment in Phase 2 Clinical Trial with Serlopitant for Refractory Chronic Cough
REDWOOD CITY, Calif., Oct. 26, 2017 /PRNewswire/ -- Menlo Therapeutics Inc., a clinical stage biopharmaceutical company developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) has initiated enrollment in a 170-subject Phase 2 trial evaluating serlopitant as a treatment for refractory chronic cough.
The TUSSIX study, MTI-110, is a multi-center, randomized, placebo-controlled study evaluating the efficacy, safety, and tolerability of serlopitant as a treatment for refractory chronic cough. The TUSSIX study will enroll approximately 170 subjects at approximately 40 clinical sites in the U.S. and U.K. Refractory chronic cough is a common condition without any approved treatments. Additional study information is available on clinicaltrials.gov (NCT03282591).
About Serlopitant
Serlopitant is a once-daily NK-1 receptor antagonist being developed for the treatment of pruritus, or itch, associated with atopic dermatitis, psoriasis, and prurigo nodularis. Serlopitant is also being evaluated as a potential treatment for refractory chronic cough, a cough which persists for greater than eight weeks despite treatment of any identified underlying cause. Menlo Therapeutics has completed two Phase 2 studies with serlopitant showing a statistically significant reduction in pruritus compared to placebo. Originally developed by Merck and licensed to Menlo Therapeutics in 2012, serlopitant has been evaluated in more than 1,000 patients and has been shown to be well-tolerated, including in patients who have received treatment for up to a year. Serlopitant is an investigational drug that is not currently approved for use in any indication.
About Menlo Therapeutics Inc.
Menlo Therapeutics Inc. is a privately held late stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus associated with various underlying dermatological conditions and for refractory chronic cough. The company has initiated a broad clinical development program for serlopitant including Phase 2 studies for the treatment of pruritus associated with atopic dermatitis, pruritus associated with psoriasis, and refractory chronic cough, and expects to start Phase 3 trials for the treatment of pruritus associated with prurigo nodularis in the first half of 2018. Menlo Therapeutics has worldwide rights to serlopitant, excluding Japan where Menlo Therapeutics has licensed serlopitant to JT Torii. Menlo is funded by leading healthcare investors. More information is available at www.menlotherapeutics.com.
SOURCE Menlo Therapeutics Inc.
Share this article